Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs
An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD strength. Much of the growth was driven by antibody-derived drugs and vaccines for treatment and prevention of COVID-19. A worrying sign was the unusually large number of drugs that saw sales decline in the past year.
05 Apr 2023
Hardman & Co Monthly: April 2023
Pantheon International Plc (PIN:LON), 326 | H&T Group plc (HAT:LON), 364 | 23andMe Holding Co. Class A (ME:NAS), 0 | Apax Global Alpha Ltd. (APAX:LON), 140 | Astellas Pharma Inc. (4503:TKS), 0 | Bausch Health Companies Inc. (BHC:NYS), 0 | Daiichi Sankyo Company, Limited (4568:TKS), 0 | Fidelity China Special Situations PLC (FCSS:LON), 220 | GlaxoSmithKline Pharmaceuticals Limited (500660:BOM), 0 | H. Lundbeck A/S Class B (HLUN.B:CSE), 0 | Hikma Pharmaceuticals Plc (HIK:LON), 1,922 | HORIZON PHARMA (HZNP:NYSE), 0 | International Biotechnology Trust PLC (IBT:LON), 680 | JAZZ PHARMACEUTICALS (JAZZ:NYSE), 0 | Jazz Pharmaceuticals Public Limited Company (JAZZ:NAS), 0 | Johnson & Johnson (JNJ:NYSE), 0 | Johnson & Johnson (JNJ:NYS), 0 | Otsuka Holdings Co., Ltd. (4578:TKS), 0 | REGENERON PHARMACEUTICALS (REGN:NYSE), 0 | Regeneron Pharmaceuticals, Inc. (REGN:NAS), 0 | Shield Therapeutics Plc (STX:LON), 4.1 | Shionogi & Co., Ltd. (4507:TKS), 0 | Sumitomo Pharma Co.Ltd. (4506:TKS), 0 | Takeda Pharmaceutical Co. Ltd. (4502:TKS), 0 | Teva Pharmaceutical Industries Limited (TEVA:TAE), 0 | UNITED THERAPEUTICS (UTHR:NYSE), 0 | United Therapeutics Corporation (UTHR:NAS), 0 | VERTEX PHARMACEUTICALS (VRTX:NYSE), 0 | Vertex Pharmaceuticals Incorporated (VRTX:NAS), 0 | Viatris, Inc. (VTRS:NAS), 0 | UCB (UCB:EBR), 0 | UCB S.A. (UCB:BRU), 0 | Sanofi (SAN:EPA), 0 | Sanofi (SAN:PAR), 0 | Pfizer Inc (PFE:NYSE), 0 | Pfizer Inc. (PFE:NYS), 0 | PFIZER LIMITED (500680:BOM), 0 | Novo Nordisk (NOVO-B:CPH), 0 | Novo Nordisk A/S Class B (NOVO.B:CSE), 0 | Novartis AG (NOT:ETR), 0 | Moderna Inc (MRNA:NYSE), 0 | Moderna, Inc. (MRNA:NAS), 0 | Merck KGaA (MRK:ETR), 0
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Hardman & Co Monthly: April 2023
Pantheon International Plc (PIN:LON), 326 | H&T Group plc (HAT:LON), 364 | 23andMe Holding Co. Class A (ME:NAS), 0 | Apax Global Alpha Ltd. (APAX:LON), 140 | Astellas Pharma Inc. (4503:TKS), 0 | Bausch Health Companies Inc. (BHC:NYS), 0 | Daiichi Sankyo Company, Limited (4568:TKS), 0 | Fidelity China Special Situations PLC (FCSS:LON), 220 | GlaxoSmithKline Pharmaceuticals Limited (500660:BOM), 0 | H. Lundbeck A/S Class B (HLUN.B:CSE), 0 | Hikma Pharmaceuticals Plc (HIK:LON), 1,922 | HORIZON PHARMA (HZNP:NYSE), 0 | International Biotechnology Trust PLC (IBT:LON), 680 | JAZZ PHARMACEUTICALS (JAZZ:NYSE), 0 | Jazz Pharmaceuticals Public Limited Company (JAZZ:NAS), 0 | Johnson & Johnson (JNJ:NYSE), 0 | Johnson & Johnson (JNJ:NYS), 0 | Otsuka Holdings Co., Ltd. (4578:TKS), 0 | REGENERON PHARMACEUTICALS (REGN:NYSE), 0 | Regeneron Pharmaceuticals, Inc. (REGN:NAS), 0 | Shield Therapeutics Plc (STX:LON), 4.1 | Shionogi & Co., Ltd. (4507:TKS), 0 | Sumitomo Pharma Co.Ltd. (4506:TKS), 0 | Takeda Pharmaceutical Co. Ltd. (4502:TKS), 0 | Teva Pharmaceutical Industries Limited (TEVA:TAE), 0 | UNITED THERAPEUTICS (UTHR:NYSE), 0 | United Therapeutics Corporation (UTHR:NAS), 0 | VERTEX PHARMACEUTICALS (VRTX:NYSE), 0 | Vertex Pharmaceuticals Incorporated (VRTX:NAS), 0 | Viatris, Inc. (VTRS:NAS), 0 | UCB (UCB:EBR), 0 | UCB S.A. (UCB:BRU), 0 | Sanofi (SAN:EPA), 0 | Sanofi (SAN:PAR), 0 | Pfizer Inc (PFE:NYSE), 0 | Pfizer Inc. (PFE:NYS), 0 | PFIZER LIMITED (500680:BOM), 0 | Novo Nordisk (NOVO-B:CPH), 0 | Novo Nordisk A/S Class B (NOVO.B:CSE), 0 | Novartis AG (NOT:ETR), 0 | Moderna Inc (MRNA:NYSE), 0 | Moderna, Inc. (MRNA:NAS), 0 | Merck KGaA (MRK:ETR), 0
- Published:
05 Apr 2023 -
Author:
Brian Moretta | Martin Hall | Mark Thomas | Riccardo Bindi -
Pages:
33
Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs
An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD strength. Much of the growth was driven by antibody-derived drugs and vaccines for treatment and prevention of COVID-19. A worrying sign was the unusually large number of drugs that saw sales decline in the past year.